Cargando…

Adherence to guidelines-recommended diagnostic testing was associated with overall survival in patients with diffuse large B-cell lymphoma after rituximab-based treatment: an observational cohort study

PURPOSE: This study assessed the impact of adherence to guidelines-recommended diagnostic testing on treatment selection and overall survival (OS) in patients with diffuse large B-cell lymphoma (DLBCL) initiated on rituximab-based first line of treatment (1-LOT). METHODS: This retrospective cohort s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Fei, Zhang, Ju, Abraham, Anup, Yan, Jessie T., Hammer, Richard D., Prime, Matthew S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381398/ https://www.ncbi.nlm.nih.gov/pubmed/35974175 http://dx.doi.org/10.1007/s00432-022-04179-8

Ejemplares similares

The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma—a pooled trials analysis
por: Fischer, Luca, et al.
Publicado: (2023)

The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B‐cell lymphoma
por: Habbous, Steven, et al.
Publicado: (2020)

Effect of response quality and line of treatment with rituximab on overall and disease-free survival of patients with B-cell lymphoma
por: Horvat, Mateja, et al.
Publicado: (2010)

Rituximab maintenance improves overall survival in follicular lymphoma: A retrospective nationwide real‐world analysis from Taiwan Cancer Registry Database
por: Huang, Huai‐Hsuan, et al.
Publicado: (2018)

Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era
por: de Oliveira Costa, Renata, et al.
Publicado: (2016)

Adherence to Guideline Recommendations in Patients with Thyroid Nodules
por: Karnchanasorn, Rudruidee, et al.
Publicado: (2017)

Primary breast diffuse large B-cell lymphoma in the era of rituximab
por: Zhang, Na, et al.
Publicado: (2016)

Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma
por: Yelvington, Bradley J.
Publicado: (2018)

Human Leukocyte Antigen Class I and II Alleles and Overall Survival in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
por: Lu, Yani, et al.
Publicado: (2011)

Recent survival trends in diffuse large B‐cell lymphoma––Have we made any progress beyond rituximab?
por: Epperla, Narendranath, et al.
Publicado: (2020)

Patient Survival With and Without Radiation Therapy for Early-Stage Diffuse Large B-Cell Lymphoma in the Era of PET and Rituximab
por: McLaughlin, Christopher, et al.
Publicado: (2022)

Polymorphisms in DNA Repair and One-Carbon Metabolism Genes and Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma
por: Wang, Sophia S, et al.
Publicado: (2008)

Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma
por: Terada, Yoshiki, et al.
Publicado: (2009)

Negative effect of hepatitis in overall and progression-free survival among patients with diffuse large B-cell lymphoma
por: Al-Mansour, Mubarak M., et al.
Publicado: (2018)

Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)
por: Kim, Yu Ri, et al.
Publicado: (2012)

Adherence to GOLD guideline treatment recommendations among pulmonologists in Turkey
por: Sen, Elif, et al.
Publicado: (2015)

Adherence to guideline recommendations for infection prophylaxis in peritoneal dialysis patients
por: Badve, Sunil V., et al.
Publicado: (2009)

Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma
por: Vacirca, Jeffrey L., et al.
Publicado: (2013)

The Kyoto Prognostic Index for patients with diffuse large B-cell lymphoma in the rituximab era
por: Kobayashi, T, et al.
Publicado: (2016)

Efficacy of rituximab combined with CHOP for treating patients with diffuse large B-cell lymphoma
por: Hu, Xin, et al.
Publicado: (2017)

Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab
por: Papageorgiou, Sotirios G., et al.
Publicado: (2022)

The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: relationship with prognostic importance and rituximab resistance
por: Liu, Yizhen, et al.
Publicado: (2020)

P1224: EFFICACY OF RITUXIMAB AND BIOSIMILAR RITUXIMAB IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA, A DANISH POPULATION BASED ANALYSIS
por: Haujir, A., et al.
Publicado: (2022)

Identification and Development of a 4-Gene Ferroptosis Signature Predicting Overall Survival for Diffuse Large B-Cell Lymphoma
por: Wu, Huitao, et al.
Publicado: (2023)

Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review
por: Zhu, Jie, et al.
Publicado: (2020)

Predicting overall survival in diffuse glioma from the presurgical connectome
por: Kesler, Shelli R., et al.
Publicado: (2022)

Population pharmacokinetics of rituximab in patients with diffuse large B‐cell lymphoma and association with clinical outcome
por: Rozman, Samo, et al.
Publicado: (2017)

Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: A meta-analysis
por: Zhou, Xuan, et al.
Publicado: (2017)

A case of irreversible bradycardia after rituximab therapy for diffuse large B-cell lymphoma
por: Ko Ko, Nway Le, et al.
Publicado: (2020)

Evaluation of the MD Anderson tumor score for diffuse large B‐cell lymphoma in the rituximab era
por: Gutierrez, Antonio, et al.
Publicado: (2020)

The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma
por: Palmieri, R., et al.
Publicado: (2019)

Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
por: Murayama, Kayoko, et al.
Publicado: (2022)

Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications
por: Papageorgiou, Sotirios G., et al.
Publicado: (2021)

The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B‐cell lymphoma
por: Kawasaki, Natsumi, et al.
Publicado: (2022)

Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma
por: Younes, Anas, et al.
Publicado: (2022)

Using decision support for population tracking of adherence to recommended asthma guidelines
por: Ahmed, Sara, et al.
Publicado: (2014)

Education Regarding and Adherence to Recommended Nutrition Guidelines among Dental Students
por: Frayna, Camille, et al.
Publicado: (2021)

Adherence to Guideline‐Recommended cancer screening among Utah cancer survivors
por: Millar, Morgan M., et al.
Publicado: (2022)

Serum Albumin Levels Strongly Predict Survival Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab-Combined Chemotherapy
por: Kaneko, Hiroto, et al.
Publicado: (2022)

Influence of adherence with guideline-driven recommendations on survival in women operated for breast cancer: Real-life evidence from Italy
por: Corrao, Giovanni, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_l7pb65pm7okdv2a7cj1oevehnu